Grants and Patents
Active grants
- Title: TRIM5alpha-Mediated Block of HIV-1 Production
Role: Principal investigator
Funded by: National Institute of Allergy and Infectious Diseases
Major goal: Elucidate the mechanism of TRIM5alpha-mediated block of HIV-1 production
Duration: September 2008 to August 2011
- Title: Small Animal Model for XMRV Infection
Role: Principal investigator
Funded by: National Institute of Allergy and Infectious Diseases
Duration: February 2011 to January 2013
- Title: Novel Tissue Engineering of Patient-Specific Islet Cells for Diabetes Therapy
Role: Co-principal investigator (with Jonathan Slack, Ph.D., University of Minnesota)
Funded by: Minnesota Partnership for Biotechnology and Medical Genomics
Duration: February 2011 to January 2013
- Title: Regulated Long-Term B-Type Natriuretic Peptide Delivery in Hypertensive Heart Disease
Role: Co-principal investigator (with Alessandro Cataliotti, M.D., Ph.D.)
Funded by: National Heart, Lung, and Blood Institute
Duration: July 2010 to June 2015
Completed grants
- Title: Self-Regulating HIV Vectors for Hemophilia A Gene Therapy
Role: Principal investigator
Funded by: National Hemophilia Foundation
Major goal: Establish HIV vectors that can regulate their own transgene expression in vivo
Duration: July 2006 to June 2009
- Title: Toward a Gene Therapy for Cocaine Addiction
Role: Co-investigator (with Stephen Brimijoin, Ph.D.)
Funded by: Minnesota Partnership for Biotechnology and Medical Genomics
Duration: May 2006 to April 2008
- Title: Detection of a Novel Human Retrovirus in Prostate Cancer Patients
Role: Principal investigator
Funded by: Mayo Clinic Prostate Cancer SPORE Career Development Award
Major goal: Conduct an epidemiological survey of XMRV infection in prostate cancer patients
Duration: October 2007 to September 2008
- Title: Activation of Pluripotent Switch for Autologous Derivation of Renewable Stem Cells
Role: Principal investigator
Funded by: Marriott Award in Individualized Medicine Disease Risk and Regenerative Medicine Initiative
Major goal: Establish a genomic modification-free iPS generation strategy
Duration: November 2008 to October 2010
- Title: iPS Technology for a Renewable Source of Pancreatic Beta Cells
Role: Principal investigator
Funded by: Bernard and Edith Waterman Awards in Individualized Medicine
Major goal: Generate iPS cells from type 1 diabetes patients and differentiate them into insulin-producing cells
Duration: July 2009 to June 2010
- Title: iPS Technology for a Renewable Source of Pancreatic Beta Cells
Role: Principal investigator
Funded by: Eisenberg Stem Cell Trust
Major goal: Generate iPS cells from type 1 diabetes patients and differentiate them into insulin-producing cells
Duration: January 2010 to June 2011
Patents
- Name: Stable HIV Vector Production
Holders: Yasuhiro Ikeda, Yasuhiro Takeuchi, Francisco Martin, Kyri Mitrophanous and Mary K. Collins
Number: U.K. patent GB0220467A
- Name: Retroviral Vector and Stable Packaging Cell Lines
Holders: Yasuhiro Ikeda, Yasuhiro Takeuchi, Francisco Martin, Kyri Mitrophanous and Mary K. Collins
Numbers: World Intellectual Property Organization WO2004022761; U.S. patent 20060258006
- Name: Materials and Methods for Improved Vaccination
Holders: Yasuhiro Ikeda, Michael Palmowski, Lucien Lopes, Mary K. Collins and Vincenzo Cerundolo
Numbers: World Intellectual Property Organization WO2004110485; U.S. patent 20060257416
- Name: Induced Pluripotent Stem Cells
Holders: Yasuhiro Ikeda, Andre Terzic, Satsuki Yamada, Alumdena Perez-Fernandez, Amber Mael and Timothy Nelson
Number: Provisional U.S. patent filed (WO 2010/017562)
|
